{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:08:15Z","timestamp":1792782495376,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical University of Vienna","id":[{"id":"https:\/\/ror.org\/05n3x4p02","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Definitive chemoradiotherapy is the standard treatment for anal cancer, but the optimal management of small (T1) tumours remains unclear, as these tumours are underrepresented in prospective trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analysed all patients with T1 anal carcinoma treated with curative intent at the Medical University of Vienna between 1990 and 2022. Patient, tumour, and treatment characteristics were extracted. Outcomes included overall survival (OS), disease-free survival (DFS), colostomy-free survival (CFS), and acute and late toxicity. Kaplan\u2013Meier estimates, log-rank tests, and univariable Cox regression were used for exploratory time-to-event analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-five patients (median age\u00a067\u00a0years, range 31\u201386; female\/male ratio 2.4:1) were included. The median prescribed dose was 58\u202fGy; 45% received concurrent chemotherapy and 35% a\u00a0brachytherapy boost. Five-year OS, DFS, and CFS were 84.7%, 80.1%, and 85.3%, respectively. Late grade\u00a03 toxicity occurred in six patients (11%), exclusively after 2D\/3D radiotherapy. No statistically significant OS or DFS differences were demonstrated for brachytherapy, chemotherapy, nodal involvement, or IMRT\/VMAT in exploratory univariable analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with T1 anal carcinoma achieved favourable long-term tumour control and organ preservation after definitive radiotherapy or chemoradiotherapy. Severe late toxicity was observed only after 2D\/3D radiotherapy; however, concurrent changes in treatment technique, dose, target volumes, and treatment era preclude attribution of this observation to any single treatment component. Numerically favourable outcomes with brachytherapy and concurrent chemotherapy were observed, but these findings remain hypothesis-generating and require validation in prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00066-026-02606-0","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:42:30Z","timestamp":1790250150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Thirty-Two Years of Radiotherapy for T1 Anal Cancer: Patterns, Outcomes, and Side-effects at a\u00a0Single Institution"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5414-6633","authenticated-orcid":false,"given":"I. M.","family":"Simek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Piroty-Dehbokry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9972-6690","authenticated-orcid":false,"given":"J.","family":"Widder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0704-9910","authenticated-orcid":false,"given":"J.","family":"Knoth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"15-16","key":"2606_CR1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s00508-020-01622-z","volume":"132","author":"E Heer","year":"2020","unstructured":"Heer\u00a0E, Hackl\u00a0M, Ferlitsch\u00a0M, Waldhoer\u00a0T, Yang\u00a0L (2020) Trends in incidence of anal cancer in Austria, 1983-2016. Wien Klin Wochenschr 132(15-16):438\u2013443. https:\/\/doi.org\/10.1007\/s00508-020-01622-z (in eng)","journal-title":"Wien Klin Wochenschr"},{"key":"2606_CR2","unstructured":"G. C. Observatory (2025) Cancer Today, International Agency for Research on Cancer (IARC) \u201cAge-Standardized Rate (World) per 100 000, Incidence and Mortality, Both sexes, in 2022; Anus; UN Regions. (ed)"},{"issue":"10","key":"2606_CR3","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1002\/1097-0142(19830515)51:10<1826::AID-CNCR2820511012>3.0.CO;2-L","volume":"51","author":"ND Nigro","year":"1983","unstructured":"Nigro\u00a0ND, Seydel\u00a0HG, Considine\u00a0B, Vaitkevicius\u00a0VK, Leichman\u00a0L, Kinzie\u00a0JJ (1983) Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer 51(10):1826\u20131829. https:\/\/doi.org\/10.1002\/1097-0142(19830515)51:10%3C1826::AID-CNCR2820511012%3E3.0.CO;2-L (in eng)","journal-title":"Cancer"},{"issue":"7","key":"2606_CR4","doi-asserted-by":"publisher","first-page":"852","DOI":"10.6004\/jnccn.2018.0060","volume":"16","author":"AB Benson","year":"2018","unstructured":"Benson\u00a0AB et\u00a0al (2018) Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J\u00a0Natl Compr Canc Netw 16(7):852\u2013871. https:\/\/doi.org\/10.6004\/jnccn.2018.0060 (in eng)","journal-title":"J Natl Compr Canc Netw"},{"issue":"9034","key":"2606_CR5","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","volume":"348","author":"SJ Arnott","year":"1996","unstructured":"Arnott\u00a0SJ et\u00a0al (1996) Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5\u2011fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 348(9034):1049\u20131054 (in eng)","journal-title":"Lancet"},{"issue":"6","key":"2606_CR6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/s1470-2045(13)70086-x","volume":"14","author":"RD James","year":"2013","unstructured":"James\u00a0RD et\u00a0al (2013) Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 \u00d7 2 factorial trial. Lancet Oncol 14(6):516\u2013524. https:\/\/doi.org\/10.1016\/s1470-2045(13)70086-x (in eng)","journal-title":"Lancet Oncol"},{"issue":"11","key":"2606_CR7","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00066-021-01842-w","volume":"197","author":"S Gerum","year":"2021","unstructured":"Gerum\u00a0S et\u00a0al (2021) Practice of radiation therapy for anal cancer in Austria\u2011a survey on behalf of the Austrian radiation oncology society gastrointestinal tumor group (\u00d6GRO-GIT). Strahlenther Onkol 197(11):953\u2013961. https:\/\/doi.org\/10.1007\/s00066-021-01842-w (in eng)","journal-title":"Strahlenther Onkol"},{"key":"2606_CR8","volume-title":"TNM Classification of Malignant Tumours","author":"JD Brierley","year":"2019","unstructured":"Brierley\u00a0JD, Gospodarowicz\u00a0MK, Wittekind\u00a0C (2019) TNM Classification of Malignant Tumours, 8th\u00a0edn. Wiley-Blackwell","edition":"8"},{"issue":"3","key":"2606_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.radonc.2008.05.001","volume":"87","author":"J Widder","year":"2008","unstructured":"Widder\u00a0J et\u00a0al (2008) Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Clin Transl Radiat Oncol 87(3):367\u2013375. https:\/\/doi.org\/10.1016\/j.radonc.2008.05.001 (in eng)","journal-title":"Radiother Oncol"},{"key":"2606_CR10","unstructured":"Aigner F, Siegel R, Werner R, Esser S, Oette M, Weyandt G (2020) Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Diagnostik, Therapie und Nachsorge von Analkanal- und Analrandkarzinomen, Langversion 1.2, 2020, AWMF-Registernummer: 081-004OL.. Accessed 17 Mar 2026"},{"issue":"4","key":"2606_CR11","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/s1470-2045(20)30753-1","volume":"22","author":"R P\u00f6tter","year":"2021","unstructured":"P\u00f6tter\u00a0R et\u00a0al (2021) MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol 22(4):538\u2013547. https:\/\/doi.org\/10.1016\/s1470-2045(20)30753-1 (in eng)","journal-title":"Lancet Oncol"},{"issue":"1","key":"2606_CR12","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.brachy.2016.07.007","volume":"16","author":"A Cordoba","year":"2017","unstructured":"Cordoba\u00a0A, Escande\u00a0A, Leroy\u00a0T, Mirabel\u00a0X, Coche-Dequ\u00e9ant\u00a0B, Lartigau\u00a0E (2017) Low-dose-rate interstitial brachytherapy boost for the treatment of anal canal cancers. Brachytherapy 16(1):230\u2013235. https:\/\/doi.org\/10.1016\/j.brachy.2016.07.007 (in eng)","journal-title":"Brachytherapy"},{"key":"2606_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.radonc.2022.03.019","volume":"171","author":"ZS Ali","year":"2022","unstructured":"Ali\u00a0ZS, Solomon\u00a0E, Mann\u00a0P, Wong\u00a0S, Chan\u00a0KKW, Taggar\u00a0AS (2022) High dose rate brachytherapy in the management of anal cancer: A review. Clin Transl Radiat Oncol 171:43\u201352. https:\/\/doi.org\/10.1016\/j.radonc.2022.03.019 (in eng)","journal-title":"Radiother Oncol"},{"issue":"3","key":"2606_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.brachy.2025.01.006","volume":"24","author":"L Tagliaferri","year":"2025","unstructured":"Tagliaferri\u00a0L et\u00a0al (2025) High-Tailored Anal canal Radiotherapy (HIT-ART): Long term results of MR image-guided interventional radiotherapy (brachytherapy) boost. Brachytherapy 24(3):439\u2013449. https:\/\/doi.org\/10.1016\/j.brachy.2025.01.006 (in eng)","journal-title":"Brachytherapy"},{"issue":"7","key":"2606_CR15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00066-024-02316-5","volume":"201","author":"M Jirkovsk\u00e1","year":"2025","unstructured":"Jirkovsk\u00e1\u00a0M, Stanku\u0161ov\u00e1\u00a0H, Kindlov\u00e1\u00a0A, Jirkovsk\u00fd\u00a0D, Lohynsk\u00e1\u00a0R (2025) Interstitial HDR brachytherapy for anal cancer-results and quality of life. Strahlenther Onkol 201(7):687\u2013698. https:\/\/doi.org\/10.1007\/s00066-024-02316-5 (in eng)","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"2606_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.21037\/jgo.2020.02.09","volume":"11","author":"S Mehta","year":"2020","unstructured":"Mehta\u00a0S, Ramey\u00a0SJ, Kwon\u00a0D et\u00a0al (2020) Impact of radiotherapy duration on overall survival in squamous cell carcinoma of the anus. J\u00a0Gastrointest Oncol 11(2):277\u2013290. https:\/\/doi.org\/10.21037\/jgo.2020.02.09","journal-title":"J Gastrointest Oncol"},{"key":"2606_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2023.100589","volume":"39","author":"P Annede","year":"2023","unstructured":"Annede\u00a0P et\u00a0al (2023) Brachytherapy boost in anal canal cancer - A GEC ESTRO PDR task force meta-analysis. Clin Transl Radiat Oncol 39:100589. https:\/\/doi.org\/10.1016\/j.ctro.2023.100589 (in eng)","journal-title":"Clin Transl Radiat Oncol"},{"issue":"7","key":"2606_CR18","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","volume":"102","author":"J Northover","year":"2010","unstructured":"Northover\u00a0J et\u00a0al (2010) Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 102(7):1123\u20131128. https:\/\/doi.org\/10.1038\/sj.bjc.6605605 (in eng)","journal-title":"Br J Cancer"},{"issue":"4","key":"2606_CR19","doi-asserted-by":"publisher","first-page":"616","DOI":"10.21037\/jgo.2019.02.06","volume":"10","author":"I Youssef","year":"2019","unstructured":"Youssef\u00a0I et\u00a0al (2019) Survival benefits and predictors of use of chemoradiation compared with radiation alone for early stage (T1-T2N0) anal squamous cell carcinoma. J\u00a0Gastrointest Oncol 10(4):616\u2013622. https:\/\/doi.org\/10.21037\/jgo.2019.02.06 (in eng)","journal-title":"J Gastrointest Oncol"},{"issue":"6","key":"2606_CR20","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/s1470-2045(25)00213-x","volume":"26","author":"A Gilbert","year":"2025","unstructured":"Gilbert\u00a0A et\u00a0al (2025) Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trial. Lancet Oncol 26(6):707\u2013718. https:\/\/doi.org\/10.1016\/s1470-2045(25)00213-x (in eng)","journal-title":"Lancet Oncol"},{"key":"2606_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109542","volume":"183","author":"V Vendrely","year":"2023","unstructured":"Vendrely\u00a0V et\u00a0al (2023) Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE. Clin Transl Radiat Oncol 183:109542. https:\/\/doi.org\/10.1016\/j.radonc.2023.109542 (in eng)","journal-title":"Radiother Oncol"},{"issue":"9","key":"2606_CR22","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s00384-020-03687-8","volume":"35","author":"TB Pedersen","year":"2020","unstructured":"Pedersen\u00a0TB, Kildsig\u00a0J, Serup-Hansen\u00a0E, Gocht-Jensen\u00a0P, Klein\u00a0MF (2020) Outcome following local excision of T1 anal cancers\u2011a systematic review. Int J Colorectal Dis 35(9):1663\u20131671. https:\/\/doi.org\/10.1007\/s00384-020-03687-8 (in eng)","journal-title":"Int J Colorectal Dis"},{"issue":"9","key":"2606_CR23","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.annonc.2021.06.015","volume":"32","author":"S Rao","year":"2021","unstructured":"Rao\u00a0S et\u00a0al (2021) Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2606). Ann Oncol 32(9):1087\u20131100. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.015 (in eng)","journal-title":"Ann Oncol"},{"issue":"4","key":"2606_CR24","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/s1470-2045(17)30104-3","volume":"18","author":"VK Morris","year":"2017","unstructured":"Morris\u00a0VK et\u00a0al (2017) Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 18(4):446\u2013453. https:\/\/doi.org\/10.1016\/s1470-2045(17)30104-3 (in eng)","journal-title":"Lancet Oncol"},{"issue":"5","key":"2606_CR25","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","volume":"28","author":"PA Ott","year":"2017","unstructured":"Ott\u00a0PA et\u00a0al (2017) Safety and antitumor activity of the anti-PD\u20111 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Facts Views Vis Obgyn 28(5):1036\u20131041. https:\/\/doi.org\/10.1093\/annonc\/mdx029 (in eng)","journal-title":"Ann Oncol"},{"issue":"10495","key":"2606_CR26","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/s0140-6736(25)00631-2","volume":"405","author":"S Rao","year":"2025","unstructured":"Rao\u00a0S et\u00a0al (2025) Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303\/InterAACT-2): a global, phase 3 randomised controlled trial. Lancet 405(10495):2144\u20132152. https:\/\/doi.org\/10.1016\/s0140-6736(25)00631-2 (in eng)","journal-title":"Lancet"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02606-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-026-02606-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02606-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:42:33Z","timestamp":1790250153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-026-02606-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":26,"alternative-id":["2606"],"URL":"https:\/\/doi.org\/10.1007\/s00066-026-02606-0","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.M.\u00a0Simek, S.\u00a0Piroty-Dehbokry, J.\u00a0Widder, R.\u00a0Schmid and J.\u00a0Knoth declare no competing interests, they see no ethical conflicts.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}